PubMed Health⌕ Search

Biomedical subjects

J el-On

Publications and source records attributed to J el-On.

At least 37 records · Page 2Linked to original sources
PubMed1990

Leishmania major: inhibition of the chemiluminescent response of human polymorphonuclear leukocytes by promastigotes and their excreted factors.

The effect of various leishmanial preparations on the chemiluminescent response (CR) of human polymorphonuclear leukocytes (PMN) was studied. Almost no CR was observed with PMN stimulated with either Leishmania promastigotes or their excreted factors (EFs). Promastigotes added to PMN stimulated with phorbol myristate acetate (PMA), at a proportion of 20 to 1, respectively inhibited approximately 80-83% of the CR activity. Leishmanial promastigotes, whether live or dead, infective or non-infective as well as whole parasite homogenates, soluble and insoluble fractions, all decreased the CR of the PMN (PMN-CR). A similar effect was also observed with leishmanial EFs. The degree of inhibition was dose dependent and increasing the amount of EFs in the reaction mixture resulted in decrease of the PMN-CR. More than 80% of the total activity of the PMN-CR was inhibited by 500 micrograms EFs added at zero time to the reaction mixture. The inhibition of PMN-CR obtained from a patient suffering from a chronic infection caused by L. major was not significantly different from that observed with PMN from normal donors. The present study suggests that the PMN-CR is impaired by the Leishmania parasites and their EFs and thus may allow a greater survival of the parasites within these cells.

Animals↗
PubMed1990

Cutaneous leishmaniasis serodiagnosis by immunoperoxidase assay.

Immunoperoxidase assay was used for the determination of serum-specific anti-leishmanial IgG antibodies in 65 patients with cutaneous leishmaniasis (CL), in 5 with visceral leishmaniasis (VL) and in 84 controls. A significant difference was observed between CL and VL sera and the control sera when either Leishmania major, L. donovani or L. aethiopica intact promastigotes were used as antigens. CL patients showed similar activity against L. major and L. donovani antigen (titers 4-64 and less than 2-64 respectively), whereas VL patients showed a higher activity with the homologous antigen L. donovani (titers 128-2,048). A high and significant correlation was demonstrated between immunoperoxidase assay, immunofluorescent assay and radioimmunoassay. No cross-reactivity was found with sera from malaria patients.

Adult↗
PubMed1987

Topical treatment of New and Old World cutaneous leishmaniasis in experimental animals.

The effect of topical treatment with 15% paromomycin sulphate and 12% methylbenzethonium chloride in white soft paraffin on cutaneous leishmaniasis in Balb/c mice was studied. The Saudi Arabian strain of Leishmania major, although being the most virulent to the mice, showed the highest susceptibility to this treatment. After 10 days treatment, parasites were totally eliminated from the treated lesion and healing was complete. 3 American strains were also tested: L. mexicana amazonensis; L. braziliensis panamensis and L. mexicana mexicana. The first was the most virulent and the most resistant to local treatment, L. b. panamensis displayed an intermediate response, and L. m. mexicana was highly susceptible. The disease relapsed in 50% of the infected treated mice within 135 days (L. major), 120 (L. m. mexicana), 25 (L. b. panamensis), and 14 days (L. m. amazonensis) after the end of the treatment.

Administration, Topical↗
PubMed1986

Leishmania major: solid phase radioimmunoassay for antibody detection in human cutaneous leishmaniasis.

A radioimmunoassay for the quantitative determination of antileishmanial antibody in sera from patients suffering from cutaneous leishmaniasis was developed. The assay, using as antigen either the soluble fraction from freeze-thawed sonicated Leishmania major (LRC-L137) promastigotes or a carbohydrate-lipid containing fraction obtained by extraction with hexane-isopropanol, was shown to be sensitive and reproducible. The sera of 95 patients were examined. These were from patients with cutaneous leishmaniasis (26 from the Jordan Valley and 13 from Sinai), kala-azar (9), malaria (24), schistosomiasis (10), toxoplasmosis (5), and leprosy (8); controls were 37 normal human sera. No significant antigen dependent differences were observed using sera from cutaneous leishmaniasis patients, although differences in the immunological response were observed between the two populations of these patients. Antileishmanial activity was not detected in sera from patients with malaria, schistosomiasis, or toxoplasmosis. Although sera from leprosy patients crossreacted with the carbohydrate-lipid containing fraction, it was nevertheless more strain specific than freeze thawed sonicated L. major.

Antibodies↗
PubMed1986

In vitro and in vivo anti-leishmanial activity of chlorpromazine alone and combined with N-meglumine antimonate.

Chlorpromazine (CPZ) was effective in vitro against leishmanial promastigotes and amastigotes. CPZ at 7.5 micrograms ml-1 killed the promastigotes of Leishmania mexicana, L. aethiopica and L. major within 24 hours of exposure. A higher concentration was required to achieve the same effect against L. donovani. N-meglumine antimonate (MGA) was only partially effective against the promastigotes of the four strains studied. Even at 1000 micrograms ml-1 total destruction of the parasites did not occur within four days of treatment. Combination chemotherapy of CPZ and MGA generally showed an additive effect against promastigotes. However, a synergistic effect was observed in the case of L. donovani promastigotes and L. major amastigotes in vitro. No significant effect was obtained against the amastigotes of L. major and L. mexicana in vivo, in cutaneous lesions of BALB/c mice.

Animals↗
PubMed1986

Recurrent cutaneous leishmaniasis: successful treatment with sodium antimony gluconate.

The case of a 15-year-old boy with recurrent cutaneous leishmaniasis is reported. Species identification was based on results of serotyping and isoenzyme analysis. The patient did not respond to rifampin combined with isoniazid or to ketoconazole. Subsequent therapy with systemic sodium antimony gluconate resulted in complete regression of the lesions.

Adolescent↗